Your browser doesn't support javascript.
loading
Real-world experience in treatment of donor-derived Hepatitis C virus in kidney transplant recipients with delayed initiation, shortened course glecaprevir/pibrentasvir versus standard of care.
Papanikolla, Johanna; McGowan, Melissa; Chunduru, Mythili; Winters, Holli; Pesavento, Todd; Smith, Rachel; Singh, Navdeep; Wellner, Michael; Sobotka, Lindsay; Nolan, Annelise.
Afiliación
  • Papanikolla J; Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  • McGowan M; Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  • Chunduru M; Department of Pharmacy, TriStar Summit Medical Center, Nashville, Tennessee, USA.
  • Winters H; Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
  • Pesavento T; Department of Internal Medicine, Nephrology Division, The Ohio State University, Columbus, Ohio, USA.
  • Smith R; Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA.
  • Singh N; Department of Surgery, Transplant Surgery Division, The Ohio State University, Columbus, Ohio, USA.
  • Wellner M; Department of Internal Medicine, Gastroenterology, Hepatology, and Nutrition Division, The Ohio State University, Columbus, Ohio, USA.
  • Sobotka L; Department of Internal Medicine, Gastroenterology, Hepatology, and Nutrition Division, The Ohio State University, Columbus, Ohio, USA.
  • Nolan A; Department of Pharmacy, The Ohio State University, Columbus, Ohio, USA.
Transpl Infect Dis ; : e14366, 2024 Sep 03.
Article en En | MEDLINE | ID: mdl-39226149
ABSTRACT

BACKGROUND:

There is limited literature describing the real-world practice of delayed initiation and shortened duration direct-acting antiviral (DAA) in kidney transplant recipients. We compared Hepatitis C virus (HCV) cure rates among kidney transplant recipients who received an HCV nucleic acid test positive (NAT +) kidney and were treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks or glecaprevir/pibrentasvir (G/P) for 8 weeks, a duration that is 4 weeks shorter than the guideline recommendation for treatment delay beyond 1-week post-transplant.

METHODS:

Retrospective study of HCV-negative adult patients who received a kidney transplant from an HCV NAT+ donor between April 2019 and April 2022 treated with either SOF/VEL for 12 weeks or G/P for 8 weeks. The primary outcome was sustained virologic response 12 weeks after completion of therapy (SVR12). Secondary outcomes included time to DAA initiation, renal function, graft loss, patient death, liver function tests, and opportunistic infections.

RESULTS:

102 kidney transplant recipients were included with 36 treated with G/P and 66 treated with SOF/VEL. All 36 (100%) treated with G/P achieved SVR12. One patient in the SOF/VEL group failed to achieve SVR12 but received additional therapy and was cured. Time to DAA initiation was similar with a mean of 4 weeks. There was no difference in AST/ALT > 3x ULN or renal function. One rejection occurred in each group. No patient death or graft loss was observed. There was no difference in cytomegalovirus and BK viremia between groups. 

CONCLUSION:

Delayed initiation of DAA therapy with 12 weeks of SOF/VEL or 8 weeks of G/P achieves SVR12 in kidney transplant recipients without significant adverse effects.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Transpl Infect Dis Asunto de la revista: TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Dinamarca